SARS-CoV-2 probes and other COVID-19 research reagents

As of June 12, 2020, IDT has produced primer and probe kits sufficient to enable approximately 35 million tests to be conducted in the US pursuant to the CDC EUA testing protocol.

IDT has received inquiries from researchers from around the world who are interested in rapidly obtaining assays and developing vaccines targeting the novel coronavirus (2019-nCoV/SARS-CoV-2) identified in Wuhan, China. Supporting these efforts, the CDC and the Chinese government have sequenced and submitted the coronavirus genome to the US NCBI GenBank® database. With our worldwide manufacturing capabilities, IDT is uniquely able to provide robust qPCR assays while avoiding contamination issues from synthesis of controls and related gene fragments.

Virus detection

Custom SARS-CoV-2 qPCR panels »

Primers and probes of unmatched accuracy and purity, delivered fast.

Don’t see what you need?

We can accommodate custom requests for your SARS-CoV-2 experiments.

Contact us

CDC qPCR detection assay »

The US Centers for Disease Control and Prevention (CDC) has designed RT-PCR assays and published a protocol for the detection of the SARS-CoV-2 virus. IDT manufactures primers and probes for this assay.

Detection assay for the Charité/Berlin protocol »

Collaborators from Charité – Universitätsmedizin Berlin Institute of Virology, German Centre for Infection Research, Tib-Molbiol, Erasmus MC, Rotterdam, and other entities designed an assay and published a RT-PCR protocol for the detection of SARS-CoV-2.  IDT manufactures primers and probes for this assay.

Luminex SARS-CoV-2 RT-PCR Assay »

Luminex Corporation has designed RT-PCR assays for the detection of SARS-CoV-2.  IDT provides primers and probes for this assay.

Vaccine development

Genes & gene fragments »

Advances in gene synthesis mean that subunit vaccines can be developed quickly from one or more antigen-presenting viral genes or peptide sequences, which circumvents the need for scientists to handle live and potentially dangerous pathogens, and eliminates the time needed to clone DNA fragments.

Use IDT double-stranded DNA fragments to create synthetic proteins designed as safe reagents for vaccine research. IDT offers 3 convenient options: linear gBlocks Gene Fragments, eBlocks Gene Fragments, or Custom Genes cloned into vectors. These are available in varying lengths and synthesis scales. Start your order, and we will help you choose the format that best fits your needs.

Virus Research

NGS solutions »

Targeted next generation sequencing (NGS) can quickly and accurately generate genomic data for viral infection identification, virus genome analysis, and surveillance of virus mutations. To meet the urgent demand for COVID-19 research tools, we are partnering with our customers to offer new target enrichment products featuring high performance and reproducibility, fast turnaround time, and endless customization and scalability.

Cas13 guide RNAs »

We can help with your Cas13 guide RNA needs. With fast turnaround, customizable scales and modifications, and multiple sizes in tubes or plates, we’re ready to support the detection of RNA viruses, like SARS-CoV-2.

Affinity Plus™ ASOs »

Our Affinity Plus (LNA) antisense oligonucleotides (ASOs) are perfect reagents for knocking-down SARS-CoV-2 for functional assessment or your research dedicated towards the development of potential treatments for COVID-19.

Media Information

IDT is honored to be the first company in the nation to have our primer and probe kits approved by the CDC for use as a key component of the CDC EUA testing protocol for the diagnosis and detection of COVID-19. We are proud to have rapidly achieved large-scale manufacturing of this key component which enables testing of millions of Americans for COVID-19.

For media inquiries about IDT’s role in the fight against COVID-19, please contact:

IDT Public Relations, idtpr@idtdna.com
Anna Blyth, ablyth@apcoworldwide.com
Iris Shaffer, ishaffer@apcoworldwide.com

Get up to date. Stay up to date.
Sign up to receive IDT news and updates.

Subscribe